Lamivudine Accord

Lamivudine, the active ingredient in Lamivudine Accord, is a nucleoside reverse transcriptase inhibitor presented as an oral dosage form for oral use. It treats Human Immunodeficiency Virus (HIV) infection and chronic hepatitis B in adults and children as prescribed. GNH USA supplies Lamivudine Accord as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide.

Lamivudine is an antiretroviral nucleoside reverse transcriptase inhibitor used in the management of viral infections.

- Human Immunodeficiency Virus (HIV) infection: reduces viral load and helps maintain immune function. - Chronic hepatitis B infection: suppresses viral replication and improves liver function.

Lamivudine may cause a range of adverse reactions, from mild to severe.

Common Side Effects: - Nausea: occasional upset stomach. - Headache: mild to moderate intensity. - Fatigue: general tiredness.

Serious or Rare Side Effects: - Lactic acidosis: buildup of lactate requiring immediate medical attention. - Severe hepatomegaly with steatosis: significant liver enlargement. - Pancreatitis: inflammation of the pancreas. - Severe skin reactions: such as Stevens‑Johnson syndrome. - Hypersensitivity: including rash, fever, and eosinophilia. - Neutropenia: marked reduction in white blood cells.

Before initiating Lamivudine, clinicians should consider several safety aspects. - Renal function: assess kidney status in patients with impairment. - Hepatic function: monitor liver enzymes, especially in chronic hepatitis B. - Lactic acidosis monitoring: watch for unexplained fatigue, abdominal pain, or rapid breathing. - Pregnancy: use only if potential benefits outweigh risks. - Drug resistance: avoid monotherapy; combine with other antiretrovirals. - Store at ambient temperature: keep below 25°C, protect from moisture and light.

Lamivudine can interact with other medicines, requiring careful management.

Major Interactions (Avoid): - Didanosine: increased risk of pancreatitis. - Stavudine: heightened mitochondrial toxicity. - Zidovudine: additive bone‑marrow suppression.

Moderate Interactions (Monitor Closely): - Tenofovir: monitor renal function when co‑administered. - Protease inhibitors (e.g., ritonavir): may increase lamivudine plasma levels. - Antacids containing aluminum or magnesium: may reduce lamivudine absorption.